Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Announces Participation in Upcoming Biotech Showcase

BiondVax Pharmaceuticals (NASDAQ: BVXV) CEO Amir Reichman will be presenting at the Biotech Showcase Conference, scheduled for Jan. 9–11, 2023. The conference is being held in San Francisco during the J.P. Morgan 41st annual Healthcare Conference. BiondVax board chair Mark Germain will also be available throughout the conference to meet with potential partners, collaborators and investors. BiondVax is a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Reichman’s presentation, which will focus on recent successful preclinical in vivo trial results of BiondVax’s inhaled COVID-19 therapy, is slated for Jan. 9, 2023. The presentation will also include upcoming pipeline plans for the company, including a nanosized VHH-antibody (“NanoAb”) targeting IL-17 for the treatment of autoimmune diseases such as psoriasis and additional NanoAbs for the treatment of additional autoimmune diseases such as asthma, psoriatic arthritis and macular degeneration. According to the company, Reichman “will describe BiondVax’s derisked R&D strategy generating a pipeline of NanoAbs all aimed at molecular targets already validated for efficient clinical results by currently approved monoclonal antibodies (‘mAbs’). Nevertheless, these mAbs underserve needs and certain large populations thereby generating a commercial opportunity for BiondVax’s NanoAbs that present superior characteristics.”

To view the full press release, visit  

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in BiondVax Pharmaceuticals Ltd. BVXV. Bookmark the permalink.

Comments are closed.